Office of the Vice President for Research

LambdaVision Incorporated (LVI)

LambdaVision Incorporated (LVI) logo

Retinal implant for the blind
www.lambdavision.com

LambdaVision, Inc. (LVI) is developing a high-resolution, protein-based retinal implant to restore vision to the millions of patients blinded by retinal degenerative diseases, including retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The patent-protected retinal implant technology developed by LambdaVision uses the light-activated protein, bacteriorhodopsin, to replace the function of the damaged photoreceptor cells. The flexible, subretinal implant is powered by incident light and does not require any external power supplies or bulky hardware on or outside the eye, and offers the potential for far greater resolution than competing electrode-based technologies. LambdaVision is currently at the pre-seed stage, but is looking for seed money to support further preclinical development.

Contact

Nicole Wagner, President and CEO